Boven E - Search Results

1

Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.

de Graaf M, Pinedo HM, Oosterhoff D, van der Meulen-Muileman IH, Gerritsen WR, Haisma HJ, Boven E. de Graaf M, et al. Among authors: boven e. Hum Gene Ther. 2004 Mar;15(3):229-38. doi: 10.1089/104303404322886084. Hum Gene Ther. 2004. PMID: 15018732

2

Beta-glucuronidase-mediated drug release.

de Graaf M, Boven E, Scheeren HW, Haisma HJ, Pinedo HM. de Graaf M, et al. Among authors: boven e. Curr Pharm Des. 2002;8(15):1391-403. doi: 10.2174/1381612023394485. Curr Pharm Des. 2002. PMID: 12052215 Review.

3

Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2.

Oosterhoff D, Witlox MA, van Beusechem VW, Haisma HJ, Schaap GR, Bras J, Kruyt FA, Molenaar B, Boven E, Wuisman PI, Pinedo HM, Gerritsen WR. Oosterhoff D, et al. Among authors: boven e. Mol Cancer Ther. 2003 Aug;2(8):765-71. Mol Cancer Ther. 2003. PMID: 12939466

4

A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.

de Graaf M, Nevalainen TJ, Scheeren HW, Pinedo HM, Haisma HJ, Boven E. de Graaf M, et al. Among authors: boven e. Biochem Pharmacol. 2004 Dec 1;68(11):2273-81. doi: 10.1016/j.bcp.2004.08.004. Biochem Pharmacol. 2004. PMID: 15498517

5

A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.

Haisma HJ, Boven E, van Muijen M, de Jong J, van der Vijgh WJ, Pinedo HM. Haisma HJ, et al. Among authors: boven e. Br J Cancer. 1992 Sep;66(3):474-8. doi: 10.1038/bjc.1992.298. Br J Cancer. 1992. PMID: 1520585 Free PMC article.

6

Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta-glucuronidase conjugate in the specific treatment of cancer.

Haisma HJ, van Muijen M, Pinedo HM, Boven E. Haisma HJ, et al. Among authors: boven e. Cell Biophys. 1994;24-25:185-92. doi: 10.1007/BF02789229. Cell Biophys. 1994. PMID: 7736523

7

Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy.

Houba PH, Leenders RG, Boven E, Scheeren JW, Pinedo HM, Haisma HJ. Houba PH, et al. Among authors: boven e. Biochem Pharmacol. 1996 Aug 9;52(3):455-63. doi: 10.1016/0006-2952(96)00248-1. Biochem Pharmacol. 1996. PMID: 8687500

8

Improved characteristics of a human beta-glucuronidase-antibody conjugate after deglycosylation for use in antibody-directed enzyme prodrug therapy.

Houba PH, Boven E, Haisma HJ. Houba PH, et al. Among authors: boven e. Bioconjug Chem. 1996 Sep-Oct;7(5):606-11. doi: 10.1021/bc960055j. Bioconjug Chem. 1996. PMID: 8889024

9

Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy.

Haisma HJ, Sernee MF, Hooijberg E, Brakenhoff RH, vd Meulen-Muileman IH, Pinedo HM, Boven E. Haisma HJ, et al. Among authors: boven e. Blood. 1998 Jul 1;92(1):184-90. Blood. 1998. PMID: 9639515 Free article.

10

The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.

Houba PH, Boven E, Erkelens CA, Leenders RG, Scheeren JW, Pinedo HM, Haisma HJ. Houba PH, et al. Among authors: boven e. Br J Cancer. 1998 Dec;78(12):1600-6. doi: 10.1038/bjc.1998.729. Br J Cancer. 1998. PMID: 9862570 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

254 results

Search Page

Filters